Jacobio Pharma Announces Breakthrough Therapy Designation ... - PR Newswire
Jacobio Pharma's KRAS G12C inhibitor, glecirasib, received breakthrough therapy designation by China's CDE for pancreatic cancer patients with KRAS G12C mutation post-standard care. This designation, based on clinical trial data, aims to expedite development and patient access. Glecirasib also has BTD for NSCLC in China.
Reference News
Jacobio Pharma's KRAS G12C inhibitor, glecirasib, received breakthrough therapy designation by China's CDE for pancreatic cancer patients with KRAS G12C mutation post-standard care. This designation, based on clinical trial data, aims to expedite development and patient access. Glecirasib also has BTD for NSCLC in China.
Jacobio Pharma's KRAS G12C inhibitor, glecirasib, received breakthrough therapy designation by China's CDE for pancreatic cancer with KRAS G12C mutation post-standard care. This follows a similar designation for NSCLC in 2022. Glecirasib's pivotal study aims to evaluate its efficacy and safety in pancreatic cancer, a condition with a 5% five-year survival rate.